Advertisement

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Aug
10
Today In Oncology
Kinase Inhibitor Approved for Nonsquamous NSCLC With HER2 TKD–Activating Mutations
Potential New Second-Line Standard of Care Emerges in Small Cell Lung Cancer
Mortality in Advanced-Stage Ovarian Cancer—Effect of Neoadjuvant Chemotherapy and Cytoreductive Surgery Case Volume
Smoking Cessation in Cancer Care: Challenges and Opportunities
GLP-1 Receptor Agonists vs Other Glucose-Lowering Drugs: Survival in Older Patients With Cancer and Diabetes
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo